Hematology — MCQs

Hematology Indian Medical PG Practice Questions and MCQs

Question 41: A 5-year-old girl presents with a history of progressively increasing pallor for 2 weeks and hepatosplenomegaly. Which of the following is the most relevant test for achieving the diagnosis?

A. Hemoglobin electrophoresis (Correct Answer)
B. Peripheral smear examination
C. Osmotic fragility test
D. Bone marrow examination

Explanation: ### Explanation **Correct Option: A. Hemoglobin electrophoresis** The clinical presentation of a 5-year-old child with progressive pallor and hepatosplenomegaly is highly suggestive of a chronic hemolytic anemia, most likely **Thalassemia Major**. In India, Thalassemia is a common cause of microcytic hypochromic anemia presenting in early childhood. **Hemoglobin electrophoresis** (or HPLC) is the "gold standard" confirmatory test for Thalassemia, as it identifies the abnormal proportions of hemoglobin (e.g., elevated HbF and HbA2 in β-thalassemia). [1] **Why other options are incorrect:** * **Peripheral smear examination (B):** While it shows microcytic hypochromic cells, target cells, and nucleated RBCs, these findings are suggestive but not diagnostic. It cannot differentiate definitively between Thalassemia and severe Iron Deficiency Anemia. * **Osmotic fragility test (C):** This is the screening test for **Hereditary Spherocytosis**. In Thalassemia, osmotic fragility is actually *decreased* (cells are more resistant to lysis), making it a non-specific finding. * **Bone marrow examination (D):** This would show erythroid hyperplasia, which occurs in all hemolytic anemias. It is an invasive procedure and is not required for the diagnosis of hemoglobinopathies. **Clinical Pearls for NEET-PG:** * **Thalassemia Major:** Usually presents between 6–24 months of age as fetal hemoglobin (HbF) levels decline. [1] * **Radiology:** Look for "Hair-on-end" appearance on skull X-ray due to extramedullary hematopoiesis. * **HPLC (High-Performance Liquid Chromatography):** Currently preferred over electrophoresis in modern clinical practice for its superior quantification of Hb fractions. * **Mentzer Index:** (MCV/RBC count) <13 suggests Thalassemia trait; >13 suggests Iron Deficiency Anemia.

Question 42: What is the earliest hematologic manifestation of megaloblastic anemia?

A. Increase in MCV
B. Hypersegmented polymorphs (Correct Answer)
C. Thrombocytopenia
D. Leukopenia

Explanation: **Explanation:** The earliest hematologic manifestation of megaloblastic anemia is the appearance of **hypersegmented neutrophils (polymorphs)** on the peripheral blood smear. **1. Why Hypersegmented Polymorphs are Correct:** Megaloblastic anemia results from impaired DNA synthesis (most commonly due to Vitamin B12 or Folate deficiency), while RNA and protein synthesis remain intact [1]. This leads to "nuclear-cytoplasmic asynchrony." In the bone marrow, granulocytic precursors are affected early. A neutrophil is considered hypersegmented if it has **$\geq$ 6 lobes** or if more than **5% of neutrophils have $ageq$ 5 lobes**. This change often precedes the development of macrocytosis and the drop in hemoglobin levels. **2. Analysis of Incorrect Options:** * **Increase in MCV (Macrocytosis):** While a hallmark of the disease, an increase in Mean Corpuscular Volume (MCV) typically occurs *after* the appearance of hypersegmented neutrophils. It is a sensitive indicator but not the earliest. * **Thrombocytopenia & Leukopenia:** These occur in later, more severe stages of the disease due to ineffective hematopoiesis affecting all cell lines (pancytopenia). They are never the initial manifestations. **3. High-Yield Clinical Pearls for NEET-PG:** * **Earliest Sign:** Hypersegmented neutrophils. * **Earliest Bone Marrow Change:** Megaloblastic erythropoiesis (specifically, the presence of megaloblasts with "open" sieve-like chromatin). * **MCV in Megaloblastic Anemia:** Usually >110 fL. * **Biochemical Markers:** Elevated **Homocysteine** (seen in both B12 and Folate deficiency) and elevated **Methylmalonic Acid (MMA)** (specific to B12 deficiency). * **Ineffective Erythropoiesis:** Leads to increased indirect bilirubin and LDH (mimicking hemolysis).

Question 43: Which disease is transmitted by all components of blood?

A. Malaria (Correct Answer)
B. Syphilis
C. Toxoplasma
D. H. pylori

Explanation: **Explanation:** **Malaria (Correct Answer):** Malaria is caused by *Plasmodium* species, which reside within red blood cells (RBCs) during the asexual stage of their life cycle [1]. However, transmission is not limited to packed RBCs. The parasites can be present in any blood component that contains even trace amounts of RBCs or contaminated plasma, including Whole Blood, Packed RBCs, Platelets, and Fresh Frozen Plasma (FFP). Because *Plasmodium* can survive at 4°C for up to 2–3 weeks, it remains viable in standard blood bank storage, making it transmissible via all components. **Incorrect Options:** * **Syphilis (*Treponema pallidum*):** The spirochete is highly sensitive to cold. It cannot survive more than 72 hours (3 days) at 4°C. Since most blood components are refrigerated, the risk of transmission is negligible in stored blood. * **Toxoplasma (*T. gondii*):** While it can be transmitted via organ transplantation or leukocyte-rich products, it is not a standard risk across all components (like FFP) as it primarily resides in nucleated cells. * **H. pylori:** This is a gastrointestinal pathogen transmitted via the fecal-oral route; it is not a blood-borne pathogen. **Clinical Pearls for NEET-PG:** * **Storage Lesion:** Malaria is the classic example of a parasite that survives refrigeration. * **Window Period:** The most common cause of post-transfusion hepatitis is Hepatitis B (due to the window period), but the most common “parasitic” post-transfusion infection is Malaria. * **TTIs (Transfusion-Transmitted Infections):** Mandatory screening in India includes HIV, HBV, HCV, Syphilis, and Malaria. * **Bacterial Contamination:** Platelets are the most likely component to cause bacterial sepsis because they are stored at room temperature (20–24°C).

Question 44: An 80-year-old asymptomatic woman was detected to have a monoclonal spike on serum electrophoresis with IgG levels of 1.5 g/dL. Bone marrow revealed 8% plasma cells. What is the most likely diagnosis?

A. Multiple myeloma
B. Indolent myeloma
C. Monoclonal gammopathy of undetermined significance (Correct Answer)
D. Waldenstrom's macroglobulinemia

Explanation: ### Explanation The correct diagnosis is **Monoclonal Gammopathy of Undetermined Significance (MGUS)**. This diagnosis is based on the International Myeloma Working Group (IMWG) criteria, which require the presence of three specific features: 1. **Serum monoclonal (M) protein < 3 g/dL.** 2. **Bone marrow plasma cells < 10%.** 3. **Absence of end-organ damage** [1] (no CRAB features: Calcium elevation, Renal insufficiency, Anemia, or Bone lesions). In this case, the patient is asymptomatic, the IgG spike is 1.5 g/dL (< 3 g/dL), and the bone marrow shows 8% plasma cells (< 10%), fitting the definition of MGUS perfectly. #### Why other options are incorrect: * **Multiple Myeloma:** Requires bone marrow plasma cells **≥ 10%** (or biopsy-proven plasmacytoma) **AND** evidence of end-organ damage (CRAB features) [1] or specific biomarkers of malignancy (e.g., plasma cells ≥ 60%). * **Indolent (Smoldering) Myeloma:** Characterized by an M-protein ≥ 3 g/dL OR bone marrow plasma cells between 10–60%, but **without** end-organ damage. This patient's values are below these thresholds. * **Waldenstrom’s Macroglobulinemia:** This is a lymphoplasmacytic lymphoma characterized by a monoclonal **IgM** spike (not IgG) and bone marrow infiltration by lymphoplasmacytic cells [2]. #### NEET-PG High-Yield Pearls: * **Risk of Progression:** MGUS carries a **1% annual risk** of progressing to Multiple Myeloma. * **Most Common Gammopathy:** MGUS is the most common plasma cell dyscrasia, especially in the elderly (found in ~3% of the population >50 years). * **Management:** Asymptomatic MGUS does not require chemotherapy; it requires "watchful waiting" with periodic monitoring of serum electrophoresis. * **CRAB Criteria:** Remember **C**alcium (>11 mg/dL), **R**enal (Cr >2 mg/dL), **A**nemia (Hb <10 g/dL), **B**one (≥1 lytic lesion on imaging) [1].

Question 45: Cryoprecipitate contains which of the following factors?

A. Factor II
B. Factor V
C. Factor VIII (Correct Answer)
D. Factor IX

Explanation: **Explanation:** Cryoprecipitate is a concentrated blood product prepared by thawing fresh frozen plasma (FFP) at 1–6°C and collecting the insoluble precipitate. It is specifically rich in five key components: **Factor VIII**, **Fibrinogen**, **von Willebrand Factor (vWF)**, **Factor XIII**, and **Fibronectin** [1]. * **Factor VIII (Correct):** Cryoprecipitate contains approximately 80–150 units of Factor VIII per unit, making it a historical treatment for Hemophilia A (though recombinant factors are now preferred) [2]. * **Factor II, IX, and X (Incorrect):** These are Vitamin K-dependent factors. They are found in FFP and Prothrombin Complex Concentrates (PCC), but they do not precipitate in the cold and are thus absent in cryoprecipitate. * **Factor V (Incorrect):** This is a labile factor found in FFP but is not concentrated in cryoprecipitate. **Clinical Pearls for NEET-PG:** 1. **Primary Indication:** The most common modern indication for cryoprecipitate is **Hypofibrinogenemia** (e.g., in DIC or massive hemorrhage) [1]. One unit of cryoprecipitate typically raises fibrinogen levels by 5–10 mg/dL. 2. **Mnemonic (F-8):** Remember the "F"s: **F**ibrinogen, **F**actor VIII, **F**actor XIII, and v**W**F (which carries Factor VIII). 3. **Dosage:** Usually administered as a "pool" of 10 units. 4. **Storage:** Once thawed, it must be transfused within 6 hours (or 4 hours if pooled in an open system) to maintain factor potency.

Question 46: A 50-year-old patient presents with abdominal discomfort for the last 2 years and a large spleen weighing 3 kg. Bone marrow aspiration is difficult. What is the most probable diagnosis?

A. Sickle cell anemia
B. Myelofibrosis (Correct Answer)
C. Hemochromatosis
D. Iron deficiency anemia

Explanation: ### Explanation The clinical presentation of massive splenomegaly (3 kg) and a "difficult" bone marrow aspiration (Dry Tap) is a classic triad for **Primary Myelofibrosis (PMF)** [1]. **1. Why Myelofibrosis is correct:** * **Massive Splenomegaly:** PMF is characterized by extensive extramedullary hematopoiesis (EMH), leading to some of the largest spleens seen in clinical practice (often crossing the midline) [1]. * **Dry Tap:** The hallmark of PMF is reactive fibroblast proliferation and collagen deposition in the bone marrow [1]. This fibrosis makes it impossible to aspirate marrow fluid, resulting in a "dry tap." Diagnosis is confirmed via a bone marrow trephine biopsy showing increased reticulin or collagen fibrosis [1]. **2. Why the other options are incorrect:** * **Sickle Cell Anemia:** In adults, this typically presents with a small, shrunken, and fibrotic spleen (**autosplenectomy**) due to repeated infarctions, rather than massive splenomegaly. * **Hemochromatosis:** While it can cause hepatomegaly and occasionally mild splenomegaly (due to portal hypertension from cirrhosis), it does not cause a 3 kg spleen or bone marrow fibrosis. * **Iron Deficiency Anemia:** This usually presents with a normal-sized spleen. If splenomegaly is present, it is mild and occurs in only about 10% of cases. **3. NEET-PG High-Yield Pearls:** * **Causes of Massive Splenomegaly:** Myelofibrosis, Chronic Myeloid Leukemia (CML), Visceral Leishmaniasis (Kala-azar), Malaria (Hyperreactive Malarial Splenomegaly), and Gaucher’s disease [1]. * **Peripheral Smear in PMF:** Look for **Leukoerythroblastic picture** (immature WBCs and RBCs) and **Teardrop RBCs (Dacrocytes)** [1]. * **Common Causes of Dry Tap:** Myelofibrosis, Hairy Cell Leukemia, Secondary deposits (Metastasis), and Aplastic Anemia.

Question 47: A 32-year-old male is diagnosed with acute myeloid leukemia. His total WBC count was less than normal initially. Which of the following factors indicates a poor prognosis in AML?

A. Monosomies of chromosomes (Correct Answer)
B. Young age
C. Patients with t(15;17)
D. Low WBC count

Explanation: **Explanation:** The prognosis of Acute Myeloid Leukemia (AML) is primarily determined by cytogenetic and molecular abnormalities. **1. Why Monosomies are the correct answer:** Cytogenetics is the most important prognostic factor in AML. **Monosomal karyotype (MK)**, defined as the presence of two or more distinct autosomal monosomies or a single monosomy in the presence of other structural abnormalities, is associated with an extremely poor prognosis and very low survival rates [1]. Specifically, monosomies of chromosomes 5 or 7 (-5, -7) are classic indicators of high-risk disease and poor response to standard chemotherapy [1]. **2. Analysis of Incorrect Options:** * **Young age:** Age is a significant prognostic factor, but **younger age (<60 years)** is generally a **favorable** factor [1]. Older patients often have poor performance status and higher rates of adverse cytogenetics. * **t(15;17):** This translocation is characteristic of **Acute Promyelocytic Leukemia (APL/M3)**. It is considered a **favorable-risk** cytogenetic marker because it responds exceptionally well to All-trans Retinoic Acid (ATRA) and Arsenic Trioxide [1]. * **Low WBC count:** In AML, a **high initial WBC count** (typically >50,000–100,000/µL) is a marker of high tumor burden and is associated with a **poor** prognosis. A low or normal initial WBC count is not a poor prognostic indicator. **Clinical Pearls for NEET-PG:** * **Favorable Prognosis:** t(8;21), inv(16), t(15;17), and NPM1 mutation (without FLT3-ITD) [1]. * **Poor Prognosis:** Monosomy 5 or 7, del(5q), 11q23 abnormalities, and **FLT3-ITD** mutations [1]. * **Auer Rods:** Pathognomonic for AML (especially M3); they are clumps of azurophilic granules. * **Treatment of choice for M3:** ATRA + Arsenic Trioxide.

Question 48: All of the following investigation findings about Haemophilia A are true, EXCEPT:

A. PTT increased
B. PT increased (Correct Answer)
C. Clotting time is increased
D. Serum levels of factor VIII are decreased

Explanation: Hemophilia A is an X-linked recessive bleeding disorder characterized by a deficiency of **Factor VIII** [1]. To answer this question, one must understand the coagulation cascade and which laboratory tests evaluate specific pathways. **Why Option B is the Correct Answer (The Exception):** * **Prothrombin Time (PT)** measures the **Extrinsic** and **Common** pathways (Factors VII, X, V, II, and I) [2]. * Since Hemophilia A involves a deficiency in Factor VIII (a component of the **Intrinsic** pathway), the PT remains **normal** [2]. An increased PT would suggest a deficiency in Factor VII, Vitamin K deficiency, or liver disease. **Analysis of Other Options:** * **A. PTT increased:** Partial Thromboplastin Time (PTT/aPTT) measures the **Intrinsic** and Common pathways (Factors XII, XI, IX, VIII, X, V, II, I) [2]. A deficiency in Factor VIII directly leads to a prolonged aPTT. * **C. Clotting time is increased:** Clotting time is a non-specific measure of the intrinsic pathway. In severe hemophilia, the time taken for whole blood to clot is prolonged. * **D. Serum levels of factor VIII are decreased:** This is the definitive biochemical hallmark of Hemophilia A. **High-Yield Clinical Pearls for NEET-PG:** * **Mixing Study:** If aPTT is prolonged, a mixing study is performed [2]. If the aPTT corrects with normal plasma, it indicates a **factor deficiency** (like Hemophilia); if it doesn't correct, it indicates a **factor inhibitor**. * **Hemophilia B:** Deficiency of Factor IX (Christmas disease); lab findings are identical to Hemophilia A. * **von Willebrand Disease (vWD):** Often confused with Hemophilia A because vWF stabilizes Factor VIII [3]. However, in vWD, the **Bleeding Time is increased** and Ristocetin cofactor assay is abnormal [3]. * **Most common site of bleeding:** Hemarthrosis (bleeding into joints, most commonly the knee).

Question 49: Bence-Jones proteins are a laboratory finding of:

A. Paget's disease
B. Multiple myeloma (Correct Answer)
C. Malignant melanoma
D. Fibrous dysplasia

Explanation: **Explanation:** **Multiple Myeloma (Option B)** is a plasma cell dyscrasia characterized by the monoclonal proliferation of plasma cells [1]. These cells produce excessive amounts of monoclonal (M) proteins. **Bence-Jones proteins** are specifically the **monoclonal free light chains** (either kappa or lambda) that are small enough to be filtered by the glomerulus and excreted in the urine [2]. A key biochemical property is their unique solubility: they precipitate when heated to 40–60°C and redissolve upon boiling (100°C). **Why other options are incorrect:** * **Paget’s Disease (Option A):** A disorder of bone remodeling characterized by increased osteoclastic and osteoblastic activity. Key markers include elevated Serum Alkaline Phosphatase (ALP) and urinary hydroxyproline, not light chains. * **Malignant Melanoma (Option C):** A melanocytic skin cancer. While it may have various tumor markers (like S100 or LDH for prognosis), it does not involve immunoglobulin production. * **Fibrous Dysplasia (Option D):** A benign bone condition where normal bone is replaced by fibrous tissue (showing a "ground-glass" appearance on X-ray). It does not involve plasma cell pathology. **High-Yield Clinical Pearls for NEET-PG:** * **Diagnosis:** Bence-Jones proteins are detected by **Urine Protein Electrophoresis (UPEP)** or Immunofixation [2]. They are *not* detected by standard urine dipsticks (which primarily sense albumin). * **Renal Impact:** These light chains are nephrotoxic and lead to **"Myeloma Kidney"** (Cast Nephropathy). * **CRAB Criteria for Myeloma:** **C**alcium elevation, **R**enal insufficiency, **A**nemia, and **B**one lesions (lytic "punched-out" lesions) [2]. * **Diagnostic Hallmark:** Bone marrow biopsy showing >10% clonal plasma cells [2].

Question 50: A patient has a Hemoglobin of 6 gm%. Which of the following should not be administered?

A. Fresh frozen plasma (Correct Answer)
B. Whole blood
C. Random donor platelets
D. Packed red cells

Explanation: **Explanation:** The patient presents with a Hemoglobin (Hb) of **6 gm%**, which indicates significant anemia. According to standard clinical guidelines, a Hb level below 7 gm% is a common threshold for a blood transfusion to restore oxygen-carrying capacity. **Why Fresh Frozen Plasma (FFP) is the Correct Answer:** FFP contains all coagulation factors but **does not contain red blood cells (RBCs)**. Therefore, it has no oxygen-carrying capacity and cannot correct anemia. Administering FFP to a patient with isolated anemia is inappropriate and carries risks of volume overload (TACO) and transfusion-related acute lung injury (TRALI) without providing any therapeutic benefit for the low hemoglobin. **Analysis of Incorrect Options:** * **Packed Red Cells (PRBCs):** This is the **treatment of choice** for symptomatic anemia. It provides a concentrated dose of RBCs to increase Hb levels while minimizing volume. * **Whole Blood:** While less commonly used today than component therapy, whole blood contains RBCs and can effectively raise hemoglobin levels, especially in cases of acute massive hemorrhage. * **Random Donor Platelets (RDP):** While RDPs are used for thrombocytopenia, they are not "contraindicated" in the same sense as FFP for anemia. However, in the context of this question, FFP is the most distinctively incorrect choice because it is often misused as a "volume expander," which is a major clinical pitfall. **NEET-PG High-Yield Pearls:** * **1 unit of PRBC** increases Hb by **1 gm/dL** and Hematocrit by **3%** in an average adult. * **FFP Indications:** Correction of multiple coagulation factor deficiencies (e.g., liver disease, DIC, Warfarin reversal), not for volume expansion or nutritional support. * **Transfusion Threshold:** Generally **7 gm/dL** in stable patients and **8 gm/dL** in patients with preexisting cardiovascular disease.

Practice by Chapter

Anemia Evaluation and Management

Practice Questions

Hemoglobinopathies

Practice Questions

Thalassemias

Practice Questions

Platelet Disorders

Practice Questions

Coagulation Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Leukemias

Practice Questions

Lymphomas

Practice Questions

Multiple Myeloma and Plasma Cell Disorders

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Transfusion Medicine

Practice Questions

Hematopoietic Stem Cell Transplantation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?